ORAGENICS INC — Director's Dealing 2019

Mar 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAGENICS INC (OGEN)
CIK: 0001174940
Period of Report: 2019-03-25

Reporting Person: Telling Fred (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-25	Common Stock	P	100000	—	Acquired	339538	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-25	Series 1 Common Stock Warrants (right to buy)	$0.75	P	50000	Acquired	2020-09-25	Common Stock (50000)	Direct
2019-03-25	Series 2 Common Stock Warrants (right to buy)	$0.90	P	50000	Acquired	2024-03-25	Common Stock (50000)	Direct

Footnotes

F1: Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units.